Pharma's Market

PHARMA WATCH LIST

SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- US Stocks Avoid Closing Down Over 1%, Again

TOP HEADLINES

» Markets | Economy | Companies

- Greek Debt Saga Back on Center Stage for Markets

PHARMA'S MARKET VIDEO

» More

Wall Street Protests 29 Apr 2010
Following a big demonstration in favor of financial regulation right outside the NYSE, with CNBC's Mike Huckman.
March on Wall Street 29 Apr 2010
Main Street takes to Wall Street today with thousands of union community activists marching to make the big banks pay, with CNBC's Mike Huckman.
Mike Huckman: Reporter's Reporter 29 Apr 2010
Original air date, June 26, 2002.
SBUX Beats the Street 21 Apr 2010
CNBC's Mike Huckman has Starbucks' earnings breakdown.

The Orange Squeeze on Dimon

16 Apr 2010

Some students at Syracuse University have a different idea rather than having JPMorgan's chairman/CEO Jamie Dimon deliver this year's commencement speech, reports CNBC's Mike Huckman.

Nasdaq Outperforms 14 Apr 2010
The Nasdaq easily outperforming the other major indexes today, with CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

Merck "Adapts" To Tredaptive Setback

Published: Tuesday, 29 Apr 2008 | 11:37 AM ET

Text Size

By: Mike Huckman
Reporter

AP
Investors are finding no solace in Merck's reaffirmation that it'll still hit its earnings numbers this year. Instead they're punishing the stock after the company announced what everyone is calling a surprise and a significant setback.

Yesterday I blogged about regulatory risk and late yesterday the Food and Drug Administration provided Merck [MRK Loading... () ] with another example of it. The agency rejected the drugmaker's cholesterol treatment formerly known as Cordaptive and now called Tredaptive (The FDA sometimes makes companies change proposed commercial drug names for any number of reasons.)

In a press release Merck didn't divulge the FDA's problem(s) with the drug, but analysts suspect it has something to do with safety issues. Tredaptive combines Niacin with a new drug to reduce the extremely bothersome facial flushing side effects of Niacin.

Anecdotally, two co-workers at CNBC told me separately in the days leading up to the FDA decision date that they'd both taken Niacin, but had to go off of it because the turned red, tingly and hot. Abbott Labs [ABT Loading... () ] markets A Niacin drug under the brand name Niaspan. ABT shares are rallying on the elimination of, at least, a near-term threat to the drug which brought in $660 million in revenue last year.

Just last week European regulatory authorities recommended approval of Tredaptive. That, perhaps, goes to the point. Schering-Plough [SGP Loading... () ] Chairman and CEO Fred Hassan made in my interview with him last week, that he believes the regulatory, political and media environment in the U.S. is putting the country at risk of ceding its drug innovation leadership position to overseas.

Indeed, Merck has suffered two FDA slapdowns in as many days. Last Friday, the agency said no to MRK and SGP's combo allergy drug and then late Monday came the Tredaptive decision.

Analysts are all over the story. Miller-Tabak healthcare analyst writes in a stinging research note to clients: "Two non-approvals in one week. Is this a record for MRK? It seems more like PFE. We had expected this drug to be a blockbuster in the middle of the next decade. Obviously this is called into question."

And Catherine Arnold at Credit Suisse says: "MRK's late stage pipeline is seen as mediocre absent Cordaptive...."

Merck has a diet and another cholesterol drug in development, but similar drugs at competitors have not fared well. CS has banked Merck and wants to do it again.

If investors didn't realize it before, this week's events (and the week is young) are a painful lesson (unless you're on the short side of the trade) that the pharma-biotech sectors are rife with risk. Not just regulatory, but also clinical. This morning before the opening bell Genentech[DNA Loading... () ] and Biogen Idec [BIIB Loading... () ] announced their late-stage test of Rituxan on lupus didn't meet its goal. Both stocks are getting hammered.